L Mazoni1, A Matrone1, M Apicella1, F Saponaro2, S Borsari1, E Pardi1, B Cosci1, I Biagioni1, P Rossi3, F Pacciardi3, A Scionti3, R Elisei1, C Marcocci1, F Cetani4. 1. Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy. 2. Department of Pathology, University of Pisa, Pisa, Italy. 3. Diagnostic and Interventional Radiology Unit, University Hospital of Pisa, Pisa, Italy. 4. Endocrine Unit 2, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy. cetani@endoc.med.unipi.it.
Abstract
PURPOSE: Conventional therapy (calcium and activated vitamin D) does not restore calcium homeostasis in patients with chronic hypoparathyroidism (HypoPT) and is associated with renal complications and reduced quality of life (QoL). The aim of this study was to evaluate in a case-control, cross-sectional study, the rate of renal complications and QoL in two sex- and age-matched cohort of patients with differentiated thyroid cancer with (n = 89) and without (n = 89) chronic post-operative HypoPT (PoHypoPT) and their relationship with the biochemical control of the disease. METHODS: Serum and urinary parameters, renal ultrasound and QoL were assessed by SF-36 and WHO-5 questionnaires. RESULTS: Forty-three (48.3%) PoHypoPT patients reported symptoms of hypocalcemia. Twenty-six (29.2%) patients were at target for all 6 parameters, 46 (51.6%) for 5. The most frequently unmet targets were gender-specific 24-h urinary calcium (44.9%) and serum calcium (37.1%). Serum phosphate, magnesium and 25(OH)D were in the normal range in > 90% of patients. Renal calcifications were found in 26 (29.2%) patients, with no correlation with 24-h urinary calcium. eGFR did not differ between patients and controls. Conversely, patients had a significant higher rate of renal calcifications and a lower SF-36, but not WHO-5, scores. SF-36 scores did not differ between PoHypoPT patients who were, or not, hypocalcemic. CONCLUSIONS: Our study shows that the rate of renal calcifications was higher in patients with PoHypoPT than in those without. This finding, together with the reduced QoL and the presence of hypocalcemic symptoms in about half patients, underscores that the treatment of chronic HypoPT with conventional therapy is suboptimal.
PURPOSE: Conventional therapy (calcium and activated vitamin D) does not restore calcium homeostasis in patients with chronic hypoparathyroidism (HypoPT) and is associated with renal complications and reduced quality of life (QoL). The aim of this study was to evaluate in a case-control, cross-sectional study, the rate of renal complications and QoL in two sex- and age-matched cohort of patients with differentiated thyroid cancer with (n = 89) and without (n = 89) chronic post-operative HypoPT (PoHypoPT) and their relationship with the biochemical control of the disease. METHODS: Serum and urinary parameters, renal ultrasound and QoL were assessed by SF-36 and WHO-5 questionnaires. RESULTS: Forty-three (48.3%) PoHypoPT patients reported symptoms of hypocalcemia. Twenty-six (29.2%) patients were at target for all 6 parameters, 46 (51.6%) for 5. The most frequently unmet targets were gender-specific 24-h urinary calcium (44.9%) and serum calcium (37.1%). Serum phosphate, magnesium and 25(OH)D were in the normal range in > 90% of patients. Renal calcifications were found in 26 (29.2%) patients, with no correlation with 24-h urinary calcium. eGFR did not differ between patients and controls. Conversely, patients had a significant higher rate of renal calcifications and a lower SF-36, but not WHO-5, scores. SF-36 scores did not differ between PoHypoPT patients who were, or not, hypocalcemic. CONCLUSIONS: Our study shows that the rate of renal calcifications was higher in patients with PoHypoPT than in those without. This finding, together with the reduced QoL and the presence of hypocalcemic symptoms in about half patients, underscores that the treatment of chronic HypoPT with conventional therapy is suboptimal.
Authors: Matthias Büttner; Laura D Locati; Monica Pinto; Cláudia Araújo; Iwona M Tomaszewska; Naomi Kiyota; E Vidhubala; Christine Brannan; Eva Hammerlid; Olga Husson; Dina Salem; Georgios Ioannidis; Eva Gamper; Juan Ignacio Arraras; Guy Andry; Johanna Inhestern; Juliane Theurer; Katherine Taylor; Susanne Singer Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958
Authors: Deborah M Mitchell; Susan Regan; Michael R Cooley; Kelly B Lauter; Michael C Vrla; Carolyn B Becker; Sherri-Ann M Burnett-Bowie; Michael Mannstadt Journal: J Clin Endocrinol Metab Date: 2012-10-05 Impact factor: 5.958
Authors: John P Bilezikian; Maria Luisa Brandi; Natalie E Cusano; Michael Mannstadt; Lars Rejnmark; René Rizzoli; Mishaela R Rubin; Karen K Winer; Uri A Liberman; John T Potts Journal: J Clin Endocrinol Metab Date: 2016-03-03 Impact factor: 5.958
Authors: Maria Luisa Brandi; John P Bilezikian; Dolores Shoback; Roger Bouillon; Bart L Clarke; Rajesh V Thakker; Aliya A Khan; John T Potts Journal: J Clin Endocrinol Metab Date: 2016-03-04 Impact factor: 5.958
Authors: F Saponaro; G Alfi; F Cetani; A Matrone; L Mazoni; M Apicella; E Pardi; S Borsari; M Laurino; E Lai; A Gemignani; C Marcocci Journal: J Endocrinol Invest Date: 2022-06-25 Impact factor: 5.467